Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
During a scientific conference on Tuesday, Johnson & Johnson (NYSE: JNJ) announced positive results from a human proof-of-concept trial with relapsed multiple myeloma patients and teclistamab, the bispecific antibody formerly known as JNJ-5957. At the American Society of Clinical Oncology's conference, which was held virtually, J&J presented interim results that strongly suggest teclistamab can make a significant difference for patients who have relapsed after receiving between two and 14 lines of treatment.
Today's cancer therapies are limited to single targets, but this early clinical-stage candidate targets both beta-cell maturation factor (BCMA) often found on cancerous cells and CD3 found on T-cells at the same time.
Image source: Getty Images.
Source Fool.com
